Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Authors:
- Mar Llamas-VelascoMLMar Llamas-Velasco
- Mercedes HospitalMHMercedes Hospital
- Anna López-FerrerALAnna López-Ferrer
- Pedro HerranzPHPedro Herranz
- Ricardo Ruíz-VillaverdeRicardo Ruíz-Villaverde
- Almudena MateuAMAlmudena Mateu
- Francisco Javier García-LatasaFGFrancisco Javier García-Latasa
- Raquel RiveraRRRaquel Rivera
- Lourdes Rodriguez Fernández-FreireLFLourdes Rodriguez Fernández-Freire
- Elena Del AlcazarEAElena Del Alcazar
- Sergio SantosSSSergio Santos
- Salvador AriasSalvador Arias
Open Access
Abstract
Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.Keywords
This publication has 40 references indexed in Scilit:
- Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional StudiesDermatology and Therapy, 2026
- Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2Dermatology and Therapy, 2026
- Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-AnalysisDermatology and Therapy, 2026
- Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque CountryDermatology and Therapy, 2025
- Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysisDermatology and Therapy, 2025
- Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical PracticeDermatology and Therapy, 2025
- Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world settingJournal of Dermatological Treatment, 2024
- Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Journal of the American Academy of Dermatology, 2020
- Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRJAMA Dermatology, 2018
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsThe Lancet, 2017